Navigation Links
A micro-RNA as a key regulator of learning and Alzheimer's disease
Date:9/23/2011

This release is available in German.

Gttingen, September 23rd, 2011. Proteins are the molecular machines of the cell. They transport materials, cleave products or transmit signals and for a long time, they have been a main focus of attention in molecular biology research. In the last two decades, however, another class of critically important molecules has emerged: small RNA molecules, including micro-RNAs. It is now well established that micro-RNAs play a key role in the regulation of cell function."A micro-RNA regulates the production of an estimated 300-400 proteins. This class of molecules can be regarded as a switch that coordinates the transition of cells from one state to another," explains Prof. Dr. Andr Fischer, scientist at the German Center for Neurodegenerative Diseases (DZNE) and Speaker of the DZNE site Gttingen. He and his team have identified a micro-RNA that regulates the learning processes and probably plays a central role in Alzheimer's disease. The researchers have shown that there is too much of a micro-RNA called "miRNA 34c" in mouse models of Alzheimer's disease, and decreasing the level of miRNA 34c in these mice can restore their learning ability. The scientists have identified a new target molecule that might be important for diagnosis and treatment of Alzheimer's disease. The studies were carried out in collaboration with scientists at the European Neuroscience Institute Gttingen, the Gttingen University, the DZNE site in Munich and researchers from Switzerland, USA and Brazil.

miRNA 34c was identified using a highly complex method called "massive parallel sequencing". With this technology, Fischer and his colleagues captured the complete RNA composition in the hippocampus the learning region of the brain and compared this with the RNA of the entire brain. They showed that miRNA 34c is enriched in the hippocampus, especially in during the time window of a few hours after a learning phase. "We suspect that the function of micro-RNA 34c is to switch off a whole range of gene products that are turned on in the learning process," Fischer said. Too much miRNA 34c would then lead to a blockade of learning which is exactly what was shown in subsequent experiments. In old mice, which do not learn as easily as their younger counterparts, there was indeed too much miRNA 34c. The miRNA-34c level was also elevated in mice that are used as specific research models of Alzheimer's disease. These mice carry a genetic mutation that can cause Alzheimer's in humans and show disturbances of memory function. Moreover, miRNA 34c seems to not only play a role in mice. Fischer and his colleagues showed these levels are also elevated in the brains of Alzheimer's patients.

In further mouse experiments, the researchers showed that miRNA 34c is actually causally involved in the pathogenesis of Alzheimer's disease and memory disorders. An artificial increase of miRNA-34c level in normal mice results in memory impairment in the animals. Secondly, as Fischer and his colleagues have shown, lowering miRNA-34c levels can restore learning ability in mouse models of Alzheimer's disease and in older mice. "Neurodegenerative diseases like Alzheimer's are associated with many factors. We hope that with the identification of micro-RNA 34c, we have found an important mediator of pathogenesis," says Fischer. "Micro-RNA 34c would then be a good candidate for the development of drugs against Alzheimer's."


'/>"/>

Contact: Daniel Bayer
daniel.bayer@dzne.de
49-228-433-02261
Helmholtz Association of German Research Centres
Source:Eurekalert

Related biology news :

1. Micro-RNA blocks the effect of insulin in obesity
2. New evidence in plants shows micro-RNA can move
3. Cancer proteins surprising role as memory regulator
4. Unraveling a new regulator of cystic fibrosis
5. Genome-wide hunts reveal new regulators of blood pressure
6. Systech International and Zetes Partner to Meet Europes Emerging Pharmaceutical Regulatory Requirements
7. Syracuse University biologist discovers key regulators for biofilm development
8. Medusa-structure of gene regulatory network: Dominance of transcription factors in cancer subtypes
9. Novel regulatory process for T cells may help explain immune system diseases
10. Saint Louis University investigators perfect new version of blood-regulator thrombin
11. Key enzyme discovered to be master regulator in protein-protein reactions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... DUBLIN , June 27, 2016 Research ... in North America 2016-2020" report to their offering. ... North America to grow at a CAGR ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:6/22/2016)... On Monday, the Department of Homeland Security (DHS) issued ... the Biometric Exit Program. The Request for Information (RFI), ... that CBP intends to add biometrics to confirm when ... , in order to deter visa overstays, to ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 2016 Eurofins announces the appointment of Sean Murray ... Scientific Inc. (ESI). Mr. Murray will bring valuable ... entrepreneurial experience in leading international business teams. As the National Division ... to uphold Eurofins, status as the global leader in bio-analytical testing ... , , ...
(Date:12/8/2016)... 8, 2016  Anaconda BioMed S.L., a pre-clinical stage ... next generation neuro-thrombectomy system for the treatment of Acute ... Jovin, MD to join its Scientific Advisory Board (SAB). ... network of scientific and clinical experts to Anaconda BioMed ... ANCD BRAIN ® to its clinical phase. The ...
(Date:12/8/2016)... PRINCETON, N.J. , Dec. 8, 2016 /PRNewswire/ ... a late-stage biopharmaceutical company focused on developing and ... is an unmet medical need, announced today the ... trial with SGX942 (dusquetide), a first-in-class Innate Defense ... (OM) in head and neck cancer patients undergoing ...
(Date:12/8/2016)... 2016  Partnering to fuel Philadelphia,s ... of Southeastern Pennsylvania (" Ben ... of Independence Blue Cross; and Safeguard Scientifics ("Safeguard") (NYSE: ... a $6 million funding initiative over a four year ... Responding to a burgeoning economic vitality in digital health, ...
Breaking Biology Technology: